



Advancing GI Patient Care 2021

SATURDAY, JULY 24, 2021

Accredited by:



This program is supported by an educational grant from
AbbVie, Janssen Biotech, Inc., Mallinckrodt Pharmaceuticals and Pfizer Inc.

IBD in Pregnancy Clinical Care Pathway

IBD Parenthood Project

Rajeev Jain, MD
TDDC – Dallas, TX

Disclosures

- Governance
 - Chief of Gastroenterology – Texas Health Dallas
 - Chair Elect – American Board Internal Medicine Board of Directors
 - Member – TDDC Clinical Governance Board
- Research
 - AbbVie
 - Eli Lilly
 - Gilead Sciences
 - UNC TOUR

Outline

- Background
 - Inflammatory Bowel Disease (IBD)
 - IBD Parenthood Project
- Clinical Care Pathways
 - Pre-conception
 - Pregnancy
 - Delivery
 - Post-partum
- Summary




Inflammatory Bowel Disease

- Immune-mediated condition of unknown etiology
- Chronic
- Relapses and remissions
- Substantial impact


Inflammatory Bowel Disease (IBD)

- Crohn's disease (CD)
 - Inflammation at any location in along the GI tract
 - 35% ileocecal, 35% ileal, 20% colonic
 - Transmural and patchy with creeping fat
 - Complications: strictures, fistulas and abscesses
 - By 10 yrs, ~50% of patients have required surgery
- Ulcerative colitis (UC)
 - Starts in rectum and continuous extension limited to colon
 - Only affects mucosal layer
- Indeterminate colitis

IBD History & Global Burden



IBD Pathogenesis



IBD in the US



**1.6
Million**

People have
IBD in the U.S.



50%


Are women and most will
have the condition during
childbearing years – from
before getting pregnant to
after birth

Fear

- Impact of IBD and its therapies on:
 - Pregnancy
 - Infant outcomes
- Impact of pregnancy on:
 - IBD
 - Maternal health



Voluntarily Childless



Background



Consensus Conference
July 26-27, 2018

Partners

Partner organizations in the development of the Clinical Care Pathway



AUTHORITY

Society specializing in the care of high-risk pregnancy, offering unique access to practice professionals, as well as like-minded, agenda-setting organizations.



EMPOWERMENT

Leading IBD patient organization, providing invaluable partnership and expertise in patient education and advocacy.



PERSPECTIVE

Not-for-profit organization dedicated to empowering women living with IBD, supported by their built-in network of like-minded patients.

Multidisciplinary Working Group

Spectrum of providers that a woman with IBD may seek treatment from before, during, and after pregnancy

Gastroenterology
Maternal-fetal medicine
Teratology
Lactation

Patient stakeholders

Goals

- Provide guidance on the continuum of care
- Best practices
- Practical resource
 - Providers
 - Patients



Publications

Gastroenterology 2019;156:1508–1524

AGA SECTION

Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group



Uma Mahadevan,¹ Christopher Robinson,² Nana Bernasko,³ Brigid Boland,⁴ Christina Chambers,⁴ Marla Dubinsky,⁵ Sonia Friedman,⁶ Sunanda Kane,⁷ Jacob Manthey,⁸ Jason Sauberan,⁹ Joanne Stone,⁵ and Rajeev Jain¹⁰

¹University of California, San Francisco, San Francisco, California; ²Bon Secours St Francis and Summerville Medical Center, Charleston, South Carolina; ³Penn State Health, Milton S. Hershey Medical Center, Hershey, Pennsylvania; ⁴University of California, San Diego, California; ⁵Icahn School of Medicine at Mount Sinai, New York, New York; ⁶Brigham and Women's Hospital, Boston, Massachusetts; ⁷Mayo Clinic, Rochester, Minnesota; ⁸American Gastroenterological Association, Bethesda, Maryland; ⁹Sharp Neonatal Research Institute, San Diego, California; and ¹⁰Texas Digestive Disease Consultants, Texas

CLINICAL GUIDELINES

Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group


Uma Mahadevan¹, Christopher Robinson², Nana Bernasko³, Brigid Boland⁴, Christina Chambers⁴, Marla Dubinsky⁵, Sonia Friedman⁶, Sunanda Kane⁷, Jacob Manthey⁸, Jason Sauberan⁹, Joanne Stone⁵, Rajeev Jain¹⁰

Inflamm Bowel Dis • Volume 25, Number 4, April 2019

Special Report


ajog.org

Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group



Uma Mahadevan¹; Christopher Robinson²; Nana Bernasko³; Brigid Boland⁴; Christina Chambers⁴; Marla Dubinsky⁵; Sonia Friedman⁶; Sunanda Kane⁷; Jacob Manthey⁸; Jason Sauberan⁹; Joanne Stone⁵; Rajeev Jain¹⁰

American Journal of Obstetrics & Gynecology APRIL 2019



Let's Talk About the Facts

Care Coordination Team

- Gastroenterologist specializing in IBD
- Obstetrician
- Maternal-fetal medicine (MFM) specialist
- Nutritionist
- Lactation specialist
- Colorectal surgeon, if needed

Care Coordination Team

Due to variation in access, availability, and preference:

IBD Care

Gastroenterologist, general
Advanced Practice Provider (APP)
Surgeon
Primary care provider
Emergency department

Obstetric Care


MFM
Obstetrician
Family practitioner
Midwife
Emergency department

Risks of IBD to a Pregnancy

- Miscarriage
- Delivery of small-for-gestational-age infant
- Premature delivery
- Poor maternal weight gain
- Complications of labor and delivery
 - Preeclampsia
 - Placental abruption
 - Increased probability of cesarean section


Role of Team Members

- MFM Specialist and Obstetrician
 - Mode of delivery
 - Type of monitoring
 - Frequency of visits
 - Prior surgery
 - laparotomy, ostomy,
 - ileal pouch-anal anastomosis (IPAA)
- Gastroenterologist
 - Coordinate IBD care
- Nutritionist




Adapted from McGuire BB. Ileal pouchanal anastomosis.

Overview of Clinical Pathway



Family Planning and Preconception



Contraception

- Safest and most effective birth control option
- Long-acting, reversible contraception (LARC)
 - Hormonal or nonhormonal intrauterine device
 - Contraceptive implant
- Preference for non-estrogen containing contraception
 - Increased risk of venous thromboembolism in IBD
- Pill efficacy may be decreased
 - Active small bowel inflammation
 - Extensive resection
 - Rapid bowel transit

Genetic Risk

- IBD Type: CD > UC
- Parent: Paternal > Maternal
 - Incidence Rate Ratio (IRR)
 - Maternal CD: 6.3
 - Maternal UC: 3.7
 - Both parents: ~30% (based on 2 small studies)
 - Multiple family members
- Age of Onset: Younger > Older

Danish Study 1977-2011

N = 8,295,773

IBD 45,780

200 million person yrs

CD 0.25%

UC 0.35%

4-6 fold increased risk

Absolute Risk: 1-2.1%

Fertility Concerns

- Rates are similar to general population IF:
 - Remission
 - No prior IBD-related surgery
 - Ileal pouch-anal anastomosis (IPAA), proctectomy & ostomies
 - Inflammation and scarring of the fallopian tubes
- Voluntarily childless 18%
- Medical therapy does **not** decrease fertility
 - Biologics, steroids, thiopurines, methotrexate and mesalamine

9-Month Plan

IBD remission

IBD monitoring

- GI visit trimester 1 or 2 and then as needed
- Labs at least every trimester: complete blood count, liver enzymes, albumin (combine with OB labs)

Maternal/fetal monitoring

- Routine antepartum care
- Trimester 3 fetal growth ultrasound
- Examine perineum for evidence of active disease
- Counseling on mode of delivery

IBD flare

IBD monitoring

- GI follow-up every 2 weeks (patient portal, live, video)
- Adjust medication
- Monitor labs, calprotectin
- Management of flares (Table 1)

Maternal/fetal monitoring

- Consider fetal growth surveillance every 4 weeks after 24 weeks
- Recommend antepartum surveillance for patients with active disease in trimester 3
- Recommend ultrasound cervical length screening at 18-22 weeks gestation with follow-up if indicated by short cervix (< 25 mm) per usual obstetric indications
- Nutrition counseling
- NST/BPP for usual indications
- Patients on steroids should have early glucose screen
- Counseling on mode of delivery

9-Month Plan

Medication (Table 2)

- Stool softeners as needed
- Appropriate antimicrobials as needed
- Aminosalicylates and thiopurine monotherapy can continue throughout
- Corticosteroids are not maintenance therapy
 - Use as indicated for flares
- Biologics should continue throughout pregnancy without interruption
 - Can time last dose in trimester 3 to deliver infant at presumed drug trough

Nutrition and weight gain


- Prenatal vitamin
 - Iron may worsen abdominal pain
- Trimester 1: check iron/B12 levels
- Adequate folate supplementation
- Monitor gestational weight gain, which can be low in IBD
- Nutrition consult if needed
 - Post-surgical changes
 - Short bowel
 - Ostomy
 - Inadequate weight gain
 - Active disease

Gestational Weight

- Risk of not achieving target gestational weight gain for BMI
 - CD 2x
 - UC 1.5x
- Inadequate gestational weight gain associated with 2x risk for small-for-gestational – age infants
- Correlation with disease activity and reduced gestational weight gain
- Inadequate gestational weight gain – 2.5x risk of preterm birth

Pregnancy & IBD Concerns

- IBD flares complicate 30-35% of pregnancies
- Active perineal disease associated with 10-fold increase for 4th degree laceration
 - Anorectal fistula/abscess
 - Rectovaginal fistula
 - Anal fissure or stenosis



Options for Flare Management

Table 1

| Laboratory values | Endoscopy | Radiologic imaging | Surgery | Medication |
|--|--|---|--|---|
| <ul style="list-style-type: none"> • Standard IBD laboratory values checked • Trends for CRP and ESR may be helpful • Fecal calprotectin • Serum drug concentrations • Possibly elevated in pregnancy: <ul style="list-style-type: none"> – ESR – CRP • Alkaline phosphatase (also elevated in lactation) • Reduced in pregnancy: <ul style="list-style-type: none"> – Hemoglobin – Albumin | <ul style="list-style-type: none"> • Perform for strong indications: <ul style="list-style-type: none"> – Determining IBD disease activity – When result will change management • Flexible sigmoidoscopy is preferred over pan-colonoscopy when possible; can be performed unsedated, unprepped, and in any trimester | <ul style="list-style-type: none"> • MRI and CT have similar diagnostic accuracy for assessing IBD • Gadolinium should be avoided in pregnancy • The cumulative radiation exposure of a single CT scan (about 50 mGy) is below the level of concern • Ultrasound, where available is appropriate for terminal ileal disease | <ul style="list-style-type: none"> • Surgical intervention may be needed for: <ul style="list-style-type: none"> – Acute refractory colitis – Perforation – Abscess – Severe hemorrhage – Bowel obstruction | <ul style="list-style-type: none"> • Manage similar to nonpregnant IBD patients • Exceptions: <ul style="list-style-type: none"> • Thiopurine-naïve patients: avoid first start in pregnancy due to concerns for distinctive rare adverse reactions • Methotrexate contraindicated • Tofacitinib: avoid due to limited human data |

CRP, C-reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; MRI, Magnetic resonance imaging.

Mahadevan U et al. *Gastroenterology*. 2019; 156: 1508-24.

Imaging During Pregnancy

- Sonography is limited after 28-30 wks gestation as fetus obscures bowel.
- MRI – safety has not been definitively proven
 - Static magnetic field, tissue heating from radiofrequency pulses, high acoustic noise level & gadolinium contrast (avoid during 1st trimester).
- CT acceptable if needed (<50 mGy) with single study
- Sonography & MRI > CT because of the lack ionizing radiation. (GRADE: Strong recommendation, very low-quality evidence)

Endoscopy During Pregnancy

- Endoscopic procedures should only be performed for strong indication & if possible deferred to 2nd trimester. (ASGE & ECCO)
 - Maternal & fetal hypoxia, teratogenicity of medications and premature birth.
 - Avoid benzodiazepines in 1st trimester
- Position: left lateral or left pelvic tilt
 - Supine position: gravid uterus compressing aorta and IVC leading to maternal hypotension and decreased placental perfusion.
- Periprocedural fetal monitoring coordinated w/OB
- In pregnant women with suspected IBD or IBD flare, we recommend use of flexible sigmoidoscopy or colonoscopy if the results will affect the antenatal management of IBD.
(GRADE: Strong recommendation, very low-quality evidence.)

Pregnancy & IBD Therapy

What medications should be stopped?

- Dibutyl Phthalate containing mesalamines
 - Asacol HD®.¹
- Methotrexate
 - Known teratogen, abortifacient.²
 - When to stop? Out of body in 1 week. Recommend 1-3 months.
- Corticosteroids
 - More of an issue with disease control than drug toxicity.
 - Low birth weight, preterm birth, gestational diabetes.
- Tofacitinib
 - Very limited human data. Animal data shows malformations [PI].
 - 158 cases (96 healthy), 11 maternal in IBD.

Pregnancy & IBD Therapy

What medications should be continued/used?

- 5-aminosalicylates
 - No increased risk of birth defects.¹
 - No increased risk of renal insufficiency.²
- Antibiotics
 - Metronidazole – low risk, but all data from bacterial vaginosis.³
 - Ciprofloxacin – low risk, but limited data. Avoid.
 - Amoxicillin-Clavulanic Acid – low risk. ? NEC not consistent when given for PROM.
- Azathioprine/6mercaptopurine
 - No increased risk of birth defects.⁴
 - Risk with combination therapy?⁵

1. *Gastroenterology*. 2014 Jan; 146 (1): 76-84; 2. *Lancet*. 344 (8922): 620-621; 3. *Curr Drug Saf*. 2015; 10 (2): 170-9;
4. *Am J Gastroent*. 2013 Mar; 108 (3): 433-40; 5. *Gastroenterology*. 2016 Jul; 151 (1): 110-9.

Pregnancy & IBD Therapy

What medications should be continued/used?


- Anti-tumor necrosis factor alpha
 - No increased risk of birth defects, infections in infant.¹
 - Continue drug through pregnancy. Stopping associated with flares.¹
 - Placental transfer, except certolizumab.
- Ustekinumab
 - Low risk [206 pregnancies in clinical trials].
 - Placental transfer.
- Vedolizumab
 - Low risk [27 preg.].²
 - Placental transfer, ? Madcam and adherence.

Timing of Last Dose of Biologics


Minimize transplacental transfer by achieving trough level at estimated date of confinement (EDC)

| | |
|---|---|
| Adalimumab | Plan Final pregnancy injection 2-3 wk before EDC and resume postpartum ^a (1-2 wk if weekly dosing) |
| Certolizumab pegol | May continue scheduled dosing throughout pregnancy. |
| Golimumab | Plan final pregnancy injection 4-6 wk before EDC and resume postpartum ^a |
| Infliximab | Plan final pregnancy infusion 6-10 wk before EDC and resume postpartum ^a (If every-4-wk dosing, then 4-5 wk before EDC) Base dosing on prepregnancy weight during pregnancy and immediate postpartum |
| Natalizumab | Plan final pregnancy infusion 4-6 wk before EDC resume postpartum ^a |
| Ustekinumab ^{b/} Vedolizumab ^b | Plan final pregnancy dose 6-10 wk before EDC and resume postpartum ^a (If every-4-week dosing, then 4-5 wk before EDC) |

Mode of Delivery Algorithm




IBD Therapy After Delivery




Anticoagulation Prophylaxis

- Any patient admitted with IBD flare
- Anticoagulant thromboprophylaxis may be extended up to 3–6 weeks postpartum in patients:
 - history of venous thromboembolic disease event or
 - other high-risk factors
- Medical therapy:
 - Unfractionated heparin, low-molecular weight heparin, and warfarin are appropriate to prescribe to breastfeeding women
 - AVOID:
 - Oral direct thrombin (Pradaxa, dabigatran) and,
 - Factor Xa inhibitors (Eliquis, apixaban; Xarelto, rivaroxaban)

Post-Delivery Care



IBD Parenthood Project



The screenshot shows the homepage of the IBD Parenthood Project website. The header is dark blue with the AGA logo and 'AGA Family of Websites' on the left, and 'HCP Resources' on the right. Below the header is a navigation bar with 'Toolkit', 'News', 'About Us', and a search bar. The main content area features a large banner with a background image of a pregnant woman and a doctor. The banner text reads: 'Planning for a family can be challenging' and 'And if you have inflammatory bowel disease (IBD), there are additional factors you may need to consider. However, with the right planning and care, women with IBD can have healthy pregnancies and healthy babies.' A 'Read More' button is located below the text. Below the banner is a section titled 'Patient Toolkit' with the text: 'Make this your "go-to" resource guide for everything you need to know about IBD and pregnancy throughout all stages of family planning.' and a 'Download Now' button. At the bottom of the page is a link: 'Let's Talk About the Facts'.

aga | AGA Family of Websites HCP Resources

IBD PARENTHOOD PROJECT

Toolkit News About Us Search

Planning for a family can be challenging

And if you have inflammatory bowel disease (IBD), there are additional factors you may need to consider. However, with the right planning and care, women with IBD can have healthy pregnancies and healthy babies.

Read More

Patient Toolkit


Make this your "go-to" resource guide for everything you need to know about IBD and pregnancy throughout all stages of family planning.

Download Now

[Let's Talk About the Facts](#)

<http://www.ibdparenthoodproject.gastro.org/>

Patient Toolkit



Flowchart: Diagnosed with IBD?

Follow this flowchart to learn who should be involved in your care and how they should work together.

[Read More >](#)



Infographic: Prepare for better care

Discover key topics to think about through all stages of family planning (conception, pregnancy and after delivery).

[Read More >](#)



Infographic: Have a healthy pregnancy

Learn what you can do to make sure things go well.

[Read More >](#)



Discussion Guide: Speak up for what you need

Start a conversation with this guide to get the care you're looking for.

[Read More >](#)



Checklist: Plan ahead

Think of questions to ask your doctors to guide open and ongoing conversations.


[Read More >](#)



Fact Sheet: Know the truth

Separate myths from facts to feel empowered on the road ahead.

[Read More >](#)



FAQ: Get answers

Read these FAQs about proper planning and care to move forward with confidence.

[Read More >](#)



Fact Sheet: Post-delivery considerations

Key considerations for managing your health and the health of your newborn.

[Read More >](#)

Summary

- IBD Parenthood Project
 - <http://www.ibdparenthoodproject.gastro.org/>
- Clinical pathways
 - Pre-conception
 - Pregnancy
 - Delivery
 - Post-partum
- Patient Toolkit

